Literature DB >> 24721981

Serious photocontact dermatitis induced by topical ketoprofen depends on the formulation.

Richard H Guy1, Hidekazu Kuma2, Masaru Nakanishi2.   

Abstract

BACKGROUND: Topical administration of ketoprofen to treat local subcutaneous pain significantly reduces gastrointestinal and cardiovascular adverse effects associated with oral delivery. However, this benefit must be weighed against the risk of photosensitisation/phototoxicity.
OBJECTIVE: To substantiate the safety and efficacy of topical ketoprofen delivery from a patch.
METHODS: Experiments were performed, and published information analysed, (a) to confirm the superior skin permeability and pharmacological activity of ketoprofen, and (b) to demonstrate the lower incidence of ketoprofen photosensitisation/phototoxicity when delivered from a topical patch.
RESULTS: Ketoprofen's photodegradation products were more photoallergic than the drug itself. The period post-ketoprofen treatment that skin should be protected from UV radiation (while the drug is cleared from the application site) was estimated.
CONCLUSIONS: Photosensitisation to ketoprofen can be mitigated by a patch formulation, which protects the drug from direct UV exposure during skin application, and reduces the formation of even more photoallergic photodegradation products.

Entities:  

Keywords:  ketoprofen; photocontact dermatitis; skin; topical patch

Mesh:

Substances:

Year:  2014        PMID: 24721981     DOI: 10.1684/ejd.2014.2332

Source DB:  PubMed          Journal:  Eur J Dermatol        ISSN: 1167-1122            Impact factor:   3.328


  2 in total

1.  The efficacy and safety of S-flurbiprofen plaster in the treatment of knee osteoarthritis: a phase II, randomized, double-blind, placebo-controlled, dose-finding study.

Authors:  Ikuko Yataba; Noboru Otsuka; Isao Matsushita; Hideo Matsumoto; Yuichi Hoshino
Journal:  J Pain Res       Date:  2017-04-11       Impact factor: 3.133

2.  The Long-Term Safety of S-Flurbiprofen Plaster for Osteoarthritis Patients: An Open-Label, 52-Week Study.

Authors:  Ikuko Yataba; Noboru Otsuka; Isao Matsushita; Hideo Matsumoto; Yuichi Hoshino
Journal:  Clin Drug Investig       Date:  2016-08       Impact factor: 2.859

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.